Fedratinib and Tofacitinib Citrate
Determining the interaction of Fedratinib and Tofacitinib Citrate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSE: Coadministration with one or more medications that may result in both moderate inhibition of CYP450 3A4 and potent inhibition of CYP450 2C19 may significantly increase the plasma concentrations of tofacitinib, which is primarily metabolized by the former isoenzyme with minor contribution from the latter. In study subjects, administration with the moderate CYP450 3A4 and potent CYP450 2C19 inhibitor fluconazole increased tofacitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by approximately 27% and 79%, respectively, compared to administration of tofacitinib alone. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased. MANAGEMENT: The dosage of tofacitinib should be reduced to 5 mg once daily when used concomitantly with one or more medications that may result in both moderate inhibition of CYP450 3A4 and potent inhibition of CYP450 2C19. Moderate inhibitors of CYP450 3A4 include amiodarone, aprepitant, ciprofloxacin, crizotinib, darunavir, dalfopristin-quinupristin, diltiazem, dronedarone, erythromycin, fluconazole, fusidic acid, grapefruit juice, imatinib, isavuconazonium, netupitant, and verapamil. Potent inhibitors of CYP450 2C19 include fluconazole, fluvoxamine, esomeprazole, lansoprazole, and omeprazole. Inhibitors of CYP450 2C19 alone are unlikely to substantially alter the pharmacokinetics of tofacitinib. References "Product Information. Xeljanz (tofacitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0
Professional:ADJUST DOSE: Coadministration with one or more medications that may result in both moderate inhibition of CYP450 3A4 and potent inhibition of CYP450 2C19 may significantly increase the plasma concentrations of tofacitinib, which is primarily metabolized by the former isoenzyme with minor contribution from the latter. In study subjects, administration with the moderate CYP450 3A4 and potent CYP450 2C19 inhibitor fluconazole increased tofacitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by approximately 27% and 79%, respectively, compared to administration of tofacitinib alone. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased.
MANAGEMENT: The dosage of tofacitinib should be reduced to 5 mg once daily when used concomitantly with one or more medications that may result in both moderate inhibition of CYP450 3A4 and potent inhibition of CYP450 2C19. Moderate inhibitors of CYP450 3A4 include amiodarone, aprepitant, ciprofloxacin, crizotinib, darunavir, dalfopristin-quinupristin, diltiazem, dronedarone, erythromycin, fluconazole, fusidic acid, grapefruit juice, imatinib, isavuconazonium, netupitant, and verapamil. Potent inhibitors of CYP450 2C19 include fluconazole, fluvoxamine, esomeprazole, lansoprazole, and omeprazole. Inhibitors of CYP450 2C19 alone are unlikely to substantially alter the pharmacokinetics of tofacitinib.
- "Product Information. Xeljanz (tofacitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: tofacitinib
Brand name: Xeljanz, Xeljanz XR
Synonyms: Tofacitinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fedratinib-Tofacitinib Extended-Release Tablets
- Fedratinib-Tofacitinib Tablets
- Fedratinib-Tofranil
- Fedratinib-Tofranil injection
- Fedratinib-Tofranil-PM
- Fedratinib-Tol-Tab
- Tofacitinib Citrate-Fedratinib Hydrochloride
- Tofacitinib Citrate-Feiba
- Tofacitinib Citrate-Feiba NF
- Tofacitinib Citrate-Feiba VH Immuno
- Tofacitinib Citrate-Feiba-VH
- Tofacitinib Citrate-Felbamate